Lonza Group AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LZAGY research report →
About the company
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle.
- CEO
- Wolfgang Wienand
- IPO
- 2010
- Employees
- 16,866
- HQ
- Basel, LU, CH
Price Chart
- Market Cap
- $50.11B
- P/E
- -146.48
- P/S
- 6.14
- P/B
- 4.41
- EV/EBITDA
- 24.20
- Div Yield
- 0.87%
- Gross Margin
- 34.63%
- Op Margin
- 21.01%
- Net Margin
- -4.21%
- ROE
- -3.10%
- ROIC
- 7.22%
- Revenue
- $6.53B · -0.65%
- Net Income
- $949.00M · 49.21%
- EPS
- $1.36 · 52.81%
- Op Income
- $1.32B
- FCF YoY
- -36.24%
- 52W High
- $73.85
- 52W Low
- $58.53
- 50D MA
- $62.83
- 200D MA
- $66.04
- Beta
- 0.85
- Avg Volume
- 67.07K
Get TickerSpark's AI analysis on LZAGY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our LZAGY coverage
Recent articles, reports, and earnings notes.
No research on LZAGY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LZAGY report →Similar companies
Peers in the same neighborhood.